Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. (Q38974167)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Julian Pardo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Isabel Marzo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

A Ramírez-Labrada

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

N López-Royuela

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

V Jarauta

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

G Azaceta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

L Palomera

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

A Anel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

J Naval

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

19 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Translational Oncology

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

121-132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25037851%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12094-014-1201-y

9 March 2020

exact match

0 references

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Sorafenib: targeting multiple tyrosine kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Map kinase signaling pathways and hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Sorafenib: a review of its use in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

RIP3: a molecular switch for necrosis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

PUMA, a potent killer with or without p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Sorafenib in patients with refractory or recurrent multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1201-Y

Insulin-like growth factor I is a dual effector of multiple myeloma cell growth

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25037851

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25037851